This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Long-term 5HT3 antagonist use for schizophrenia: clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014
One systematic review and six randomized controlled trials were identified regarding the use of 5HT3 antagonists for the treatment of schizophrenia.
Subject indexing assigned by CRD
Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT3 Receptor Antagonistss
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: firstname.lastname@example.org
Date abstract record published